Adding Triptorelin to Breast CA Chemo May Up Ovarian Recovery

This article originally appeared here.
Share this content:
Adding Triptorelin to Breast CA Chemo May Up Ovarian Recovery
Adding Triptorelin to Breast CA Chemo May Up Ovarian Recovery

TUESDAY, Dec. 22, 2015 (HealthDay News) -- For premenopausal women with breast cancer, chemotherapy plus the luteinizing hormone-releasing hormone analogue (LHRHa) triptorelin is associated with higher long-term probability of ovarian function recovery, according to a study published in the Dec. 22/29 issue of the Journal of the American Medical Association.

Matteo Lambertini, M.D., from the Istituto Nazionale per la Ricerca sul Cancro in Genova, Italy, and colleagues examined the long-term results of LHRHa-induced ovarian suppression during breast cancer chemotherapy. Two hundred eighty-one premenopausal women with stage I to III hormone-receptor positive or hormone-receptor negative breast cancer were enrolled and randomized to chemotherapy plus LHRHa (148 patients) or chemotherapy alone (control; 133 patients). Participants were followed for a median of 7.3 years.

The researchers found that the five-year cumulative incidence estimate of menstrual resumption was 72.6 percent in the LHRHa group and 64.0 percent in the control group (hazard ratio [HR], 1.28; 95 percent confidence interval [CI], 0.98 to 1.68; P = 0.07; age-adjusted HR, 1.48; 95 percent CI, 1.12 to 1.95; P = 0.006). The five-year cumulative incidence of pregnancy was 2.1 and 1.6 percent in the LHRHa and control groups, respectively (HR, 2.56; 95 percent CI, 0.68 to 9.60; P = 0.14; age-adjusted HR, 2.40; 95 percent CI, 0.62 to 9.22; P = 0.20).

"Concurrent administration of triptorelin and chemotherapy, compared with chemotherapy alone, was associated with higher long-term probability of ovarian function recovery, without a statistically significant difference in pregnancy rate," the authors write.

Abstract
Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters


More in Home

FDA OKs Doptelet for Liver Dz Patients Undergoing Procedures

FDA OKs Doptelet for Liver Dz Patients Undergoing ...

Doptelet reduces the need for platelet transfusion or any rescue therapy on day of procedure

Slower Decline in Lung Function With Anthocyanin Intake

Slower Decline in Lung Function With Anthocyanin Intake

Slower annual rates of decline in FEV1 and FVC for those in highest quartile of anthocyanin intake

Bioengineering Feasible for Airway Reconstruction

Bioengineering Feasible for Airway Reconstruction

Bioengineered tracheal and bronchial reconstruction reported using stented aortic matrices

is free, fast, and customized just for you!

Already a member?

Sign In Now »